Paclitaxel, estramustine and carboplatin combination chemotherapy after initial docetaxel-based chemotherapy in castration-resistant prostate cancer

Oncology

Volumn 76, Issue 6, 2009, Pages 442-446

  Sella, A ^a,b   Yarom, N ^a   Zisman, A ^a   Kovel, S ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b ASSAF HAROFEH MEDICAL CENTER   (Israel)

Author keywords

Carboplatin; Castration resistant prostate cancer; Docetaxel; Estramustine; Paclitaxel

Indexed keywords

CALCITRIOL; CARBOPLATIN; DOCETAXEL; ESTRAMUSTINE; OXALIPLATIN; PACLITAXEL; PROSTATE SPECIFIC ANTIGEN; ANTINEOPLASTIC AGENT; TAXOID;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; BRAIN HEMORRHAGE; CANCER SURVIVAL; CASTRATION; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG DOSE REGIMEN; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; NEUROPATHY; PRIORITY JOURNAL; PROSTATE CANCER; TREATMENT RESPONSE; URINARY TRACT INFECTION; DRUG RESISTANCE; MIDDLE AGED; PROSTATE TUMOR; TIME; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DRUG RESISTANCE, NEOPLASM; ESTRAMUSTINE; HUMANS; MALE; MIDDLE AGED; PACLITAXEL; PROSTATIC NEOPLASMS; TAXOIDS; TIME FACTORS; TREATMENT OUTCOME;

EID: 65449122774     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000217264     Document Type: Article

References (25)

1. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, et al: Docetaxel and estramustine compared with mitoxan-trone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-1520.
2. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-1512.
3. Petrylak DP: New paradigms for advanced prostate cancer. Rev Urol 2007;9(suppl 2): S3-S12.
4. Beckman KW, Fleming MT, Scher HI, Slovin SF, Ishill NM, Heller G, et al: Second-line chemotherapy for prostate cancer: patient characteristics and survival. Clin Prostate Cancer 2005;4:86-90.
5. Berthold DR, Sternberg CN, Tannock IF: Management of advanced prostate cancer after first-line chemotherapy. J Clin Oncol 2005;23:8247-8252.
6. Kelly WK, Curley T, Slovin S, Heller G, McCaffrey J, Bajorin D, et al: Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. J Clin Oncol 2001;19:44-53.
7. Bubley GJ, Carducci M, Dahut W, Dwason N, Daliani D, Eisenberger M, et al: Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999;17:3461-3467.
8. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
9. Saad F, Gleason DM, Murray R, Tchekmedy-ian S, Venner P, Lacombe L, et al: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94:1458-1468.
10. http: //www.fda.gov/ohrms/dockets/AC/07/briefing/2007-4309b1-03-GPC.pdf.
11. http: //ctep.cancer.gov/forms/CTCAEv3.pdf.
12. Sternberg CN, Dumez H, Van Poppel H, et al: Multicenter randomized EORTC trial 30021of docetaxel + oblimersen and docetaxel in patients (pts) with hormone refractory prostate cancer (HRPC) (abstract 144). Proc 2007Prostate Cancer Symp, Orlando, 2007.
13. Jankovic B, Beardsley E, Chi KN: Rechallenge with docetaxel as second-line chemotherapy in patients with metastatic hormone refractory prostate cancer (HRPC) after previous docetaxel: a population based analysis (abstract 196). 2008Genitourinary Cancer Symp, San Francisco, 2008.
14. Petrioli R, Pascucci A, Francini E, Marsili S, Sciandivasci A, De Rubertis G, et al: Weekly high-dose calcitriol and docetaxel in patients with metastatic hormone-refractory prostate cancer previously exposed to doceta xel. BJU Int 2007;100:775-779.
15. Beer TM, Ryan CW, Venner PM, Petrylak DP, Chatta GS, Ruether JD, et al: Intermittent chemotherapy in patients with meta-static androgen-independent prostate cancer: results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel. Cancer 2008;112:326-330.
16. Nakabayashi M, Sartor O, Jacobus S, Regan MM, McKearn D, Ross RW, et al: Response to docetaxel/carboplatin-based chemotherapy as first-and second-line therapy in patients with metastatic hormone-refractory prostate cancer. BJU Int 2008;101:308-312.
17. Mathew P, DiPaola R: Taxane refractory prostate cancer. J Urol 2007;178:S36-S41.
18. Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB, et al: Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2trial. Lancet 2003;361:2099-2106.
19. Belani CP, Fossella F: Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced non small cell lung carcinoma (TAX 326). Cancer 2005;104:2766-2774.
20. Dimopoulos MA, Bakoyannis C, Georgoulias V, Papadimitriou C, Moulopoulos LA, Deliveliotis C, et al: Docetaxel and cisplatin combination chemotherapy in advanced carcinoma of the urothelium: a multicenter phase II study of the Hellenic Cooperative Oncology Group. Ann Oncol 1999;10:1385-1388.
21. Feinstein TM, Appleman LJ, Friedland DM, et a l: Phase II trial of oxaliplatin and docetax-el in patients with castration-resistant prostate cancer (CRPC) treated with up to two prior chemotherapeutic regimens (abstract 155). 2008 Genitourinary Cancer Symp, San Francisco, 2008.
22. Sartor AO, Petrylak DP, Witjes JA, et al: Satraplatin in patients with advanced hormone-refractory prostate cancer (HRPC): overall survival (OS) results from the phase III satraplatin and prednisone against refractory cancer (SPARC) trial (abstract 5003). J Clin Oncol 2008 ASCO Annu Meet Proc, Chicago, Ill. 2008, vol 26.
23. Oh WK, Tay MH, Huang J: Is there a role for platinum chemotherapy in the treatment of patients with hormone-refractory prostate cancer? Cancer 2007;109:477-486.
24. Culine S, Demery M, Lamy PJ, Iborra F, Avancies C, Pinguet F: Docetaxel and cisplatin in patients with metastatic androgen independent prostate cancer and circulating neuroendocrine markers. J Urol 2007;178:844-848.
25. http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4309b1-03-G.